Therapy Detail

Therapy Name VE-821
Therapy Description

VE-821 is a small molecule inhibitor of ATR, which may inhibit cell growth and enhance the sensitivity of chemotherapeutics (PMID: 22825331).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
VE-821 ATR Inhibitor 9 VE-821 is a small molecule inhibitor of ATR, which may inhibit cell growth and enhance the sensitivity of chemotherapeutics (PMID: 22825331).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ARID1A Q456* colorectal cancer sensitive VE-821 Preclinical - Cell culture Actionable In a preclinical study, colorectal cancer cells homozygous for ARID1A Q456* were sensitive to VE-821 in in vitro assays, demonstrating decrease cell survival (PMID: 27958275). 27958275
ARID1A mutant ovarian clear cell carcinoma sensitive VE-821 Preclinical - Cell culture Actionable In a preclinical study, ovarian clear cell carcinoma cells harboring an ARID1A mutation were sensitive to VE-821 in in vitro assays, demonstrating decreased cell survival (PMID: 27958275). 27958275
Clinical Trial Phase Therapies Title Recruitment Status